EMEA-001501-PIP07-20
Key facts
| Invented name |
Dupixent
|
| Active substance |
dupilumab
|
| Therapeutic area |
Dermatology
|
| Decision number |
P/0153/2021
|
| PIP number |
EMEA-001501-PIP07-20
|
| Pharmaceutical form(s) |
Solution for injection (in pre-filled syringe)
|
| Condition(s) / indication(s) |
Treatment of chronic spontaneous urticaria
|
| Route(s) of administration |
Subcutaneous use
|
| Contact for public enquiries |
sanofi-aventis recherche & développement
Tel. +33 1697 45695 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|